88 related articles for article (PubMed ID: 17786730)
1. Infusion of rituximab over 90 minutes on an out-patient basis is safe and improves resource utilization.
El-Agnaf MR; McCoy C; Ong YL; Eswedi AH; Black B; Ramadan KM
Leuk Lymphoma; 2007 Sep; 48(9):1875-7. PubMed ID: 17786730
[No Abstract] [Full Text] [Related]
2. Rapid-infusion rituximab in lymphoma treatment.
Provencio M; Cerdeira S; Bonilla F; Sánchez A; España P
Ann Oncol; 2006 Jun; 17(6):1027-8. PubMed ID: 16322113
[No Abstract] [Full Text] [Related]
3. Safe administration of iodine-131 tositumomab after repeated infusion-related reactions to rituximab.
Hayslip J; Fenning R
Oncologist; 2007 Mar; 12(3):338-40. PubMed ID: 17405899
[TBL] [Abstract][Full Text] [Related]
4. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
5. Sixty-minute infusion rituximab protocol allows for safe and efficient workflow.
Dotson E; Crawford B; Phillips G; Jones J
Support Care Cancer; 2016 Mar; 24(3):1125-9. PubMed ID: 26268782
[TBL] [Abstract][Full Text] [Related]
6. Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion.
Rigamonti C; Volta C; Colombi S; Forti L; Savinelli F; Gaidano G; Bartoli E
Leukemia; 2001 Jan; 15(1):186-7. PubMed ID: 11243389
[No Abstract] [Full Text] [Related]
7. Rapid infusion of rituximab over 60 min.
Tuthill M; Crook T; Corbet T; King J; Webb A
Eur J Haematol; 2009 Apr; 82(4):322-5. PubMed ID: 19220420
[TBL] [Abstract][Full Text] [Related]
8. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
9. A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center.
Chiang J; Chan A; Shih V; Hee SW; Tao M; Lim ST
Int J Hematol; 2010 Jun; 91(5):826-30. PubMed ID: 20461562
[TBL] [Abstract][Full Text] [Related]
10. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.
Foran JM; Cunningham D; Coiffier B; Solal-Celigny P; Reyes F; Ghielmini M; Johnson PW; Gisselbrecht C; Bradburn M; Matthews J; Lister TA
Ann Oncol; 2000; 11 Suppl 1():117-21. PubMed ID: 10707792
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for side effects during first infusion of rituximab-definition of a low risk group.
Hagberg H; Holmbom E
Med Oncol; 2000 Aug; 17(3):218-21. PubMed ID: 10962533
[TBL] [Abstract][Full Text] [Related]
12. Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution.
Salar A; Casao D; Cervera M; Pedro C; Calafell M; Abella E; Alvarez-Larrán A; Besses C
Eur J Haematol; 2006 Oct; 77(4):338-40. PubMed ID: 16856919
[TBL] [Abstract][Full Text] [Related]
13. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
Byrd JC; Murphy T; Howard RS; Lucas MS; Goodrich A; Park K; Pearson M; Waselenko JK; Ling G; Grever MR; Grillo-Lopez AJ; Rosenberg J; Kunkel L; Flinn IW
J Clin Oncol; 2001 Apr; 19(8):2153-64. PubMed ID: 11304767
[TBL] [Abstract][Full Text] [Related]
14. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study.
Schwartzberg LS; Stepanski EJ; Walker MS; Mathias S; Houts AC; Fortner BV
Support Care Cancer; 2009 Jan; 17(1):91-8. PubMed ID: 18592276
[TBL] [Abstract][Full Text] [Related]
15. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.
Sokol JA; Landau L; Lauer SA
Ophthalmic Plast Reconstr Surg; 2009; 25(4):322-4. PubMed ID: 19617799
[TBL] [Abstract][Full Text] [Related]
16. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
Pels H; Schulz H; Schlegel U; Engert A
Onkologie; 2003 Aug; 26(4):351-4. PubMed ID: 12972702
[TBL] [Abstract][Full Text] [Related]
17. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy.
Dillman RO
Cancer Metastasis Rev; 1999; 18(4):465-71. PubMed ID: 10855789
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of left ventricle function after treatment with rapid-infusion rituximab in patients with non-Hodgkin lymphoma.
Provencio M; Sanchez A; Maximiano C; Cantos B; Méndez M; Bonilla F
Leuk Lymphoma; 2009 Oct; 50(10):1642-6. PubMed ID: 19757315
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma.
Lossos IS; Morgensztern D; Blaya M; Alencar A; Pereira D; Rosenblatt J
Leuk Lymphoma; 2007 Aug; 48(8):1630-2. PubMed ID: 17701596
[No Abstract] [Full Text] [Related]
20. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
Davis TA; Maloney DG; Grillo-López AJ; White CA; Williams ME; Weiner GJ; Dowden S; Levy R
Clin Cancer Res; 2000 Jul; 6(7):2644-52. PubMed ID: 10914705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
